Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 500

1.

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.

Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E.

Mol Pharmacol. 2007 Aug;72(2):477-84. Epub 2007 May 25.

PMID:
17526600
[PubMed - indexed for MEDLINE]
Free Article
2.

Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.

Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, Conn PJ.

J Pharmacol Exp Ther. 2006 Jul;318(1):173-85. Epub 2006 Apr 11.

PMID:
16608916
[PubMed - indexed for MEDLINE]
Free Article
3.

Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.

Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK.

J Pharmacol Exp Ther. 2000 Jan;292(1):76-87.

PMID:
10604933
[PubMed - indexed for MEDLINE]
Free Article
4.

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD.

Psychopharmacology (Berl). 2005 Apr;179(1):271-83. Epub 2005 Feb 17.

PMID:
15717213
[PubMed - indexed for MEDLINE]
5.

Group II and group III metabotropic glutamate receptor agonists depress synaptic transmission in the rat spinal cord dorsal horn.

Gerber G, Zhong J, Youn D, Randic M.

Neuroscience. 2000;100(2):393-406.

PMID:
11008177
[PubMed - indexed for MEDLINE]
6.

A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.

Galici R, Echemendia NG, Rodriguez AL, Conn PJ.

J Pharmacol Exp Ther. 2005 Dec;315(3):1181-7. Epub 2005 Aug 25.

PMID:
16123306
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist.

Benneyworth MA, Smith RL, Sanders-Bush E.

Neuropsychopharmacology. 2008 Aug;33(9):2206-16. Epub 2007 Oct 24.

PMID:
17957214
[PubMed - indexed for MEDLINE]
Free Article
9.

Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.

Sanger H, Hanna L, Colvin EM, Grubisha O, Ursu D, Heinz BA, Findlay JD, Vivier RG, Sher E, Lodge D, Monn JA, Broad LM.

Neuropharmacology. 2013 Mar;66:264-73. doi: 10.1016/j.neuropharm.2012.05.023. Epub 2012 May 30.

PMID:
22659090
[PubMed - indexed for MEDLINE]
10.

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).

Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.

J Pharmacol Exp Ther. 2007 Apr;321(1):308-17. Epub 2007 Jan 4.

PMID:
17204749
[PubMed - indexed for MEDLINE]
Free Article
11.

Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors.

Gewirtz JC, Chen AC, Terwilliger R, Duman RC, Marek GJ.

Pharmacol Biochem Behav. 2002 Sep;73(2):317-26.

PMID:
12117585
[PubMed - indexed for MEDLINE]
13.

Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture.

Ahnaou A, Dautzenberg FM, Geys H, Imogai H, Gibelin A, Moechars D, Steckler T, Drinkenburg WH.

Eur J Pharmacol. 2009 Jan 28;603(1-3):62-72. doi: 10.1016/j.ejphar.2008.11.018. Epub 2008 Nov 17.

PMID:
19046965
[PubMed - indexed for MEDLINE]
14.

Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.

Molinaro G, Traficante A, Riozzi B, Di Menna L, Curto M, Pallottino S, Nicoletti F, Bruno V, Battaglia G.

Mol Pharmacol. 2009 Aug;76(2):379-87. doi: 10.1124/mol.109.056580. Epub 2009 May 13.

PMID:
19439499
[PubMed - indexed for MEDLINE]
Free Article
15.

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).

Fell MJ, Svensson KA, Johnson BG, Schoepp DD.

J Pharmacol Exp Ther. 2008 Jul;326(1):209-17. doi: 10.1124/jpet.108.136861. Epub 2008 Apr 18.

PMID:
18424625
[PubMed - indexed for MEDLINE]
Free Article
16.

Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment.

Picconi B, Pisani A, Centonze D, Battaglia G, Storto M, Nicoletti F, Bernardi G, Calabresi P.

Brain. 2002 Dec;125(Pt 12):2635-45.

PMID:
12429591
[PubMed - indexed for MEDLINE]
Free Article
17.

Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex.

Zhai Y, George CA, Zhai J, Nisenbaum ES, Johnson MP, Nisenbaum LK.

Neuropsychopharmacology. 2003 Jan;28(1):45-52.

PMID:
12496939
[PubMed - indexed for MEDLINE]
Free Article
18.

Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.

Caraci F, Molinaro G, Battaglia G, Giuffrida ML, Riozzi B, Traficante A, Bruno V, Cannella M, Merlo S, Wang X, Heinz BA, Nisenbaum ES, Britton TC, Drago F, Sortino MA, Copani A, Nicoletti F.

Mol Pharmacol. 2011 Mar;79(3):618-26. doi: 10.1124/mol.110.067488. Epub 2010 Dec 15.

PMID:
21159998
[PubMed - indexed for MEDLINE]
Free Article
19.

Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors.

Gewirtz JC, Marek GJ.

Neuropsychopharmacology. 2000 Nov;23(5):569-76.

PMID:
11027922
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk